For US Healthcare Professionals Only
Indolent ISMAdvanced SMPDGFRA GIST
Get updates for /ism/#sign-up
  Burden of ISM  
  About AYVAKIT  
  Efficacy  

  Safety  
  Dosing  
  Patient Profiles  
  Resources   
Access and SupportDownloadable ResourcesFAQConnect with UsSM Peer Directory
Indolent ISMAdvanced SMPDGFRA GIST

Patients with ISM can experience a high symptom burden that may impact work and daily life5,6

Patient portrayal

Select each of the icons below to learn more
Symptoms Statistics Graphic65% Statistics Graphic80% Statistics Graphic76% Statistics Graphic
65%
of patients reported experiencing nervous system disorders*
80%
of patients reported experiencing GI disorders*
76%
of patients reported experiencing skin and subcutaneous tissue disorders*

*Data based on ongoing medical history events in the PIONEER study (N=212). Events ≥10% in 1 or both trial arms from 3 of the organ classes include pruritus, urticaria pigmentosa, urticaria, rash maculo-papular for skin and subcutaneous tissue disorders; headache, dizziness, migraine, memory impairment, disturbance in attention for nervous system disorders; and diarrhea, abdominal pain, nausea, gastroesophageal reflux disease, abdominal distension, constipation for GI disorders.6

Patients may also take multiple symptom-directed therapies and visit HCPs frequently due to their ISM6†
symptom burden graphic
In the same patient survey, of the patients with moderate to severe ISM (n=32), 72% reported visiting HCPs ≥7 times in 1 year6†
HCP Visits in 1 Year, as Reported by Patients With Moderate to Severe ISM (n=32)6†
HCP visits chart graphic

†In the Blueprint Medicines–sponsored TouchStone SM Patient Survey, US adults with a self-reported SM diagnosis (N=56) completed an online survey of 100 items. An analysis was conducted in patients with ISM (n=37), including 32 patients with moderate to severe ISM (defined as an ISM-SAF TSS ≥28) and results were analyzed using descriptive statistics. These analyses were made from the TouchStone SM Patient Survey but have not been published.6

Historically, there have been no approved therapies for ISM5
icon triangle down navy
Learn about the first and only approved treatment option for ISM1
About Ayvakit
GI=gastrointestinal; HCP=healthcare provider; OTC=over the counter; SM=systemic mastocytosis.
Expand +
INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).

Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of <50 x 109/L.

IMPORTANT SAFETY INFORMATION
INDICATION & IMPORTANT SAFETY INFORMATION

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC; <1% were Grade 3. Depending on the severity, withhold AYVAKIT and then resume at the same dose, or permanently discontinue AYVAKIT.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective contraception during treatment with AYVAKIT and for 6 weeks after the final dose. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks following the final dose.

Adverse Reactions—The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors or inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here to see the full Prescribing Information for AYVAKIT.

References:

  1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; May 2023.
  2. Kristensen T et al. Am J Hematol. 2014;89(5):493-498.
  3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372.
  4. Ungerstedt J et al. Cancers. 2022;14(16):3942.
  5. Pardanani A. Am J Hematol. 2023;98(7):1097-1116.
  6. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2023.
  7. Gülen T et al. J Intern Med. 2016;279(3):211-228.
  8. Theoharides TC et al. N Engl J Med. 2015;373(2):163-172.
  9. Gotlib J et al. NEJM Evidence. 2023;2(6). Published online May 23, 2023. doi:10.1056/EVIDoa2200339
  10. Gilreath JA et al. Clin Pharmacol. 2019;11:77-92.
  11. Evans EK et al. Sci Transl Med. 2017;9(414):eaao1690.
  12. Padilla B et al. Orphanet J Rare Dis. 2021;16(1):434.
  13. van Anrooij B et al. Allergy. 2016;71(11):1585-1593.
  14. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited April 24, 2024]. (WHO Classification of Tumours Series, 5th ed.; vol. 11). Available from: https://tumourclassification.iarc.who.int/chapters/63
  15. Dranitsaris G et al. J Oncol Pharm Pract. Published online December 27, 2023. doi:10.1177/10781552231221149
  16. Siebenhaar F et al. Immunol Allergy Clin North Am. 2014;34(2):433-447.
  17. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.
  18. Akin C, ed. Mastocytosis: A Comprehensive Guide. Springer; 2020.